Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Novara – page 97

2 684 clinical trials in Novara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Novara at a glance
2 684
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 684 trials in Novara

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Thyroid cancer+1

Not yet recruiting

Study of levothyroxine sodium plus liothyronine sodium vs levothyroxine sodium to control TSH in advanced thyroid cancer patients on tyrosine kinase inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine Sodium
  • Sponsor:Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.

Benign prostatic hyperplasia

Not yet recruiting

Effect of serenoa repens on chronic prostate inflammation in men with benign prostatic hyperplasia: a phase III randomized study

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Serenoa repens
  • Sponsor:Azienda Ospedaliero Universitaria Careggi

Metachromatic leukodystrophy

Not yet recruiting

Long‑Term Monitoring of Malignancy Risk in Early‑Onset Metachromatic Leukodystrophy Patients Treated with atidarsagene autotemcel

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Sponsor:Orchard Therapeutics (Europe) Limited

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Muscular dystrophy

Not yet recruiting

Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

Hepatocellular carcinoma

Not yet recruiting

Phase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

Primary immunodeficiency syndrome

Not yet recruiting

Autologous CD4+ T-Cell Gene Therapy for X-linked Hyper-IgM Syndrome Type 1 in Patients with X-linked Hyper-IgM Syndrome Type 1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telethon_028
  • Sponsor:Fondazione Telethon Ets

Transitional cell carcinoma metastatic

Not yet recruiting

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Novara

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on hematologic malignancies and solid tumors, investigating innovative treatments for various cancer types including leukemia, breast cancer, and lung cancer.

  • Advanced breast cancer therapies
  • Chronic myeloid leukemia treatments
  • Non-small cell lung cancer interventions

Studies evaluating combination therapies and targeted treatments to improve patient outcomes.

02 Cardiovascular Studies

Research focusing on heart failure prevention and treatment strategies, particularly exploring new drug combinations and their impact on cardiovascular outcomes.

  • Heart failure risk reduction
  • Cardiovascular death prevention
  • Chronic kidney disease management

Innovative approaches combining multiple therapeutic agents to address cardiovascular risks.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Sjögren's Syndrome and rheumatoid arthritis, with emphasis on novel therapeutic approaches.

  • Biomarker-guided treatments
  • Long-term safety evaluations
  • Innovative therapeutic combinations

Focus on developing targeted therapies for better disease management and patient care.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.